Tavapadon eased Parkinson's symptoms, but its key advantage is untested

An experimental once-daily Parkinson's pill called tavapadon improved movement and daily function more than placebo in a phase 3 trial, and the drug is now under regulatory review [s1][s2]. But its central selling point — that its selective action spares patients the impulsive behaviour and daytime sleepiness linked to older dopamine agonists — has not actually been tested against those drugs, an independent evidence review concluded [s2].

Tavapadon, developed by Cerevel and now AbbVie, is an oral, once-daily selective agonist of the D1 and D5 dopamine receptors [s1]. That is a deliberate departure from the dopamine agonists in common use, which act on the D2 and D3 receptors and carry a well-known burden of non-motor side effects, including impulse-control disorders such as compulsive gambling [s1]. Levodopa, the mainstay treatment, works but tends to produce disabling movement complications over years of use [s1]. The pitch for a D1/D5 drug is motor benefit without those specific trade-offs.

What TEMPO-2 found

TEMPO-2 was a phase 3, double-blind, placebo-controlled trial at 75 sites across 13 countries, enrolling adults aged 40–80 with early-stage Parkinson's disease of less than three years' duration [s1]. Between January 2020 and February 2024, 304 participants were randomly assigned to flexible-dose tavapadon (5–15 mg once daily) or placebo for 27 weeks: 151 to the drug and 153 to placebo [s1].

The primary endpoint combined the movement and daily-function parts (Parts II and III) of the Movement Disorder Society Unified Parkinson's Disease Rating Scale, where a larger drop means improvement [s1]. Scores fell by a least-squares mean of 10.3 points on tavapadon versus 1.2 points on placebo — a treatment difference of 9.1 points (95% CI 6.5 to 11.7; p<0.0001) [s1].

The drug was harder to stay on. Overall, 38% of the tavapadon group discontinued the trial versus 15% on placebo, most commonly because of adverse events, which drove withdrawal in 24% of tavapadon patients against 4% on placebo [s1]. Adverse events of any kind occurred in 76% of tavapadon patients versus 55% on placebo, with nausea (30% vs 3%), headache (17% vs 5%) and dizziness (16% vs 3%) the most common [s1]. The investigators reported a low incidence of somnolence and impulse-control disorders, but noted the short observation period limits what can be said about longer-term tolerability [s1].

What the independent synthesis adds

A separate systematic review, meta-analysis and GRADE certainty assessment of selective D1/D5 agonists — published while tavapadon was under regulatory review — pooled the trial evidence for the whole drug class [s2]. Across seven trials totalling 1,540 participants, five of which entered the quantitative analysis, tavapadon improved the combined MDS-UPDRS Parts II and III score by 10.55 points versus placebo in early-stage monotherapy (95% CI 7.99 to 13.11), and increased good "on" time by 1.09 hours per day (95% CI 0.57 to 1.61) in patients already on levodopa [s2]. The review graded the motor benefit at moderate certainty [s2].

Its sharpest point is about what the evidence does not show. "Its proposed neuropsychiatric advantage over D2/D3 agonists remains untested," the authors wrote, because no trial used an active comparator and none ran longer than 27 weeks [s2]. In other words, the case that tavapadon is gentler than existing dopamine agonists rests on the absence of those side effects in short, placebo-controlled studies — not on a direct contest against the drugs it is meant to improve upon [s2].

Why it matters

Parkinson's care is a series of trade-offs between symptom control and drug side effects, so a new mechanism is genuinely welcome — but the reason to want it is a comparison that has not yet been run. TEMPO-2 shows tavapadon beats a placebo on motor scores over about six months, at the cost of more nausea and dropouts [s1]. Whether it delivers on the promise that sells it — fewer impulse-control and sleep problems than a D2/D3 agonist over years of treatment — is a question the existing trials were not designed to answer [s2]. Health Newspapers has separately examined the evidence linking green space to Parkinson's outcomes and an exhaled-breath signal studied as an early risk marker.

What to watch

An extension study is under way to test tavapadon's longer-term safety and efficacy [s1]. The decisions that will matter for patients are whether regulators approve it and, if so, whether anyone funds the head-to-head, longer trials that could confirm or deflate its central claim [s1][s2].

This article describes research and regulatory status and is not medical advice or a treatment recommendation.

Sources

• Safety, tolerability, and efficacy of flexible-dose tavapadon for Parkinson's disease (TEMPO-2): a phase 3, randomised, placebo-controlled, double-blind trial — The Lancet Neurology, 16 July 2026
• Efficacy, safety and certainty of evidence for selective D1/D5 dopamine receptor partial agonists in Parkinson's disease: a systematic review, meta-analysis and GRADE assessment — Neurological Sciences, 15 August 2026